id590543487
Between 2012 and 2021, not only did those firms spend 61 million, 93 percent of which came from realized gains from stock-based pay. In other words, the senior executives who decided to make payouts via buybacks and dividends were simultaneously enriching themselves, as the vast majority of their income came from the inflated price of the company stocks.
✏️ Data on how much the drug companies are profit driven, not just for their shareholders, but for the executives themselves.
Link to original
🔗 View Highlight